Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms, including memory impairments and cognitive deficits. Hallmarks of AD pathology are amyloid-beta (Aβ) deposition forming neuritic plaques and neurofibrillary tangles (NFTs). For many years, AD drug development has mainly focused on directly targeting the Aβ aggregation or the formation of tau tangles, but this disease has no cure so far. Other common characteristics of AD are synaptic abnormalities and dysfunctions such as synaptic damage, synaptic loss, and structural changes in the synapse. Those anomalies happen in the early stages of the disease before behavioural symptoms have occurred. Therefore, better understanding the mechanisms underlying the synaptic dysfunction found in AD and targeting the synapse, especially using early treatment windows, can lead to finding novel and more effective treatments that could improve the lives of AD patients. Researchers have recently started developing different disease-modifying treatments targeting the synapse to rescue and prevent synaptic dysfunction in AD. The main objectives of these new strategies are to halt synaptic loss, strengthen synaptic connections, and improve synaptic density, potentially leading to the rescue or prevention of cognitive impairments. This article aims to address the mechanisms of synaptic degeneration in AD and discuss current strategies that focus on the synapse for AD therapy. Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impairs memory and causes cognitive and behavioural deficits. Scientists worldwide have tried to find a treatment that can reverse or rescue AD symptoms, but there is no cure so far. One prominent characteristic of AD is the brain atrophy caused by significant synaptic loss and overall neuronal damage, which starts at the early stages of the disease before other AD hallmarks such as neuritic plaques and NFTs. The present review addresses the underlying mechanisms behind synaptic loss and dysfunction in AD and discusses potential strategies that target the synapse.

Dysregulation of Neuronal Protein Synthesis in Alzheimer’s Disease

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s Disease

Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer's Disease.

Deregulated Local Protein Synthesis in the Brain Synaptosomes of a Mouse Model for Alzheimer’s Disease

Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome

Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease.

Non-coding RNAs in Regulation of Protein Aggregation and Clearance Pathways: Current Perspectives Towards Alzheimer's Research and Therapy

Transcriptomics study of neurodegenerative disease: emphasis on synaptic dysfunction mechanism in Alzheimer's disease.

Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease.

Targeting the Synapse in Alzheimer’s Disease

Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer's Disease Brain

MicroRNAs and synapse turnover in Alzheimer's disease

The synapse as a treatment avenue for Alzheimer’s Disease

Suppression of the Kinase for Elongation Factor 2 Alleviates Mglur-Ltd Impairments in a Mouse Model of Alzheimer's Disease.

Transcriptional Regulation and Its Misregulation in Alzheimer’s Disease

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease

Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

mRNA and circRNA mislocalization to synapses are key features of Alzheimer's disease

Targeting Synaptic Pathology in Alzheimer’s Disease